These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Inhibition of binding of the platelet-activating factor AGEPC to platelets by the AGEPC analog rac-3-(N-n-octadecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate (CV-3988).
    Author: Valone FH.
    Journal: Biochem Biophys Res Commun; 1985 Jan 16; 126(1):502-8. PubMed ID: 3970703.
    Abstract:
    CV-3988, rac-3-(N-n-octadecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate, is a specific inhibitor of the platelet-activating activity of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine (AGEPC or PAFacether). Concentrations of CV-3988 between 10(-8) and 10(-7) M inhibited AGEPC-induced aggregation of washed human platelets in a dose-related manner (IC50 = 2.9 +/- 1.1 X 10(-8) M CV-3988) whereas concentrations of CV-3988 as high as 4 X 10(-6) M did not diminish platelet aggregation by thrombin or adenosine diphosphate. The binding of [3H] AGEPC to platelets was inhibited by CV-3988 in a concentration-dependent manner (IC50 = 6.7 +/- 1.8 X 10(-8) M). Compared to AGEPC, CV-3988 has a 1000-fold lower affinity for the AGEPC receptor. CV-3988 did not stimulate platelet metabolism of AGEPC as assessed by thin-layer chromatographic analysis of [3H] AGEPC extracted from platelet suspensions after four hours of incubation. Thus these studies indicate that CV-3988 inhibits platelet activation by AGEPC by inhibiting binding of AGEPC to its specific platelet receptor.
    [Abstract] [Full Text] [Related] [New Search]